The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...

Significant improvements in skin toxicity were observed by week 6 in all patients treated with HT-001 in the phase 2a ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized ...

Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.

Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.

The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) ...